Skip to main content

LBT-3627

Longevity Biotech is currently developing LBT-3627 as a novel, potentially disease-modifying, neuroprotective agent for neuroimmune conditions such as Parkinson’s Disease. LBT-3627 is a Hybridtide™ that selectively targets the VPAC2 receptor. Vasoactive Intestinal Peptide (VIP) is a well-known anti-inflammatory agent that was discovered over 50 years ago, and its receptors (VPAC1 and VPAC2) are expressed on the surface of immune cells, neurons, and several other tissues.

Longevity Biotech published preclinical results indicating LBT-3627’s neuroprotective activities, which included reduced numbers of inflammatory microglia, increased survival of dopaminergic neurons, and improved striatal densities in preclinical models of Parkinson’s Disease.

PERIPHERAL IMMUNOMODULATION

LBT-3627 rebalances the two halves of the immune system (e.g. pro- vs. anti-inflammatory) and restores a natural-like immune profile. In animal models, this has led to disease-modifying results. Through careful preclinical studies, it has been confirmed that LBT-3627 clearly rebalances peripheral T Cell function while also delivering central neuroprotective outcomes. This unique product profile is highly differentiated from other approaches, such as cell and gene therapy. These approaches often entail complicated and expensive manufacturing processes which are challenging to deliver in a clinical setting. These therapies also bear some safety concerns as it is difficult to ‘stop’ or withdraw a cell and gene therapy from an individual.

Our straightforward approach is similar to other common medicines (ie. insulin) and delivers robust disease-modifying potential.

Immune Rebalancing source: Abad & Tan J Mol Neurosci (2018) 66:102–113 - Adapted